Your browser doesn't support javascript.
loading
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)].
Plimack, Elizabeth R; Powles, Thomas; Stus, Viktor; Gafanov, Rustem; Nosov, Dmitry; Waddell, Tom; Alekseev, Boris; Pouliot, Frédéric; Melichar, Bohuslav; Soulières, Denis; Borchiellini, Delphine; McDermott, Raymond S; Vynnychenko, Ihor; Chang, Yen-Hwa; Tamada, Satoshi; Atkins, Michael B; Li, Chenxiang; Perini, Rodolfo; Rhoda Molife, L; Bedke, Jens; Rini, Brian I.
Afiliação
  • Plimack ER; Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: Elizabeth.Plimack@fccc.edu.
  • Powles T; Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, London, UK; Queen Mary University of London, London, UK.
  • Stus V; Dnipro State Medical University, Dnipro, Dnipropetrovsk Oblast, Ukraine.
  • Gafanov R; Russian Scientific Center of Roentgenology and Radiology, Moscow, Russia.
  • Nosov D; Central Clinical Hospital With Outpatient Clinic, Moscow, Russia.
  • Waddell T; The Christie NHS Foundation Trust, Manchester, UK.
  • Alekseev B; P. A. Herzen Moscow Oncology Research Institute, Ministry of Health of the Russian Federation, Moscow, Russia.
  • Pouliot F; CHU of Québec and Laval University, Québec, QC, Canada.
  • Melichar B; Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic.
  • Soulières D; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada.
  • Borchiellini D; Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France.
  • McDermott RS; Adelaide and Meath Hospital, University College Dublin, Belfield, Dublin, Ireland.
  • Vynnychenko I; Sumy Regional Oncology Center, Sumy State University, Sumy, Sumy Oblast, Ukraine.
  • Chang YH; Taipei Veterans General Hospital, Taipei, Taiwan.
  • Tamada S; Bell Land General Hospital, Osaka, Japan.
  • Atkins MB; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA.
  • Li C; Merck & Co., Inc., Rahway, NJ, USA.
  • Perini R; Merck & Co., Inc., Rahway, NJ, USA.
  • Rhoda Molife L; MSD UK, London, UK.
  • Bedke J; University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany.
  • Rini BI; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Eur Urol ; 84(5): e123-e124, 2023 Nov.
Article em En | MEDLINE | ID: mdl-37666734
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Eur Urol Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Revista: Eur Urol Ano de publicação: 2023 Tipo de documento: Article